Trial Profile
A Prospective, Randomized, Open Label Study of Piperacillin/Tazobactam Versus Imipenem/Cilastin for Empirical Therapy of Febrile Patients With Neutropenia After Hematopoietic Stem Cell Transplantation
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Mar 2016
Price :
$35
*
At a glance
- Drugs Piperacillin/tazobactam (Primary) ; Imipenem/cilastatin
- Indications Bacterial infections; Febrile neutropenia
- Focus Therapeutic Use
- 03 Dec 2012 New trial record